NYSE:CHEChemed Stock Price, Forecast & News

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CHE stock has increased by 14.8% and is now trading at $475.25. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chemed.

Chemed is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Chemed.

Chemed will be holding an earnings conference call on Wednesday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chemed Co. (NYSE:CHE) released its quarterly earnings results on Tuesday, April, 28th. The company reported $3.68 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.65 by $0.03. The company earned $515.80 million during the quarter, compared to analyst estimates of $523.04 million. Chemed had a return on equity of 35.99% and a net margin of 11.60%. The company's revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.92 EPS. View Chemed's earnings history.

Chemed announced a quarterly dividend on Tuesday, May 19th. Stockholders of record on Thursday, May 28th will be paid a dividend of $0.32 per share on Wednesday, June 17th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date is Wednesday, May 27th. View Chemed's dividend history.

4 Wall Street analysts have issued 1 year price targets for Chemed's stock. Their forecasts range from $490.00 to $535.00. On average, they anticipate Chemed's stock price to reach $515.00 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View analysts' price targets for Chemed.

News coverage about CHE stock has trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chemed earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Chemed.

Chemed saw a decline in short interest in June. As of June 30th, there was short interest totaling 197,500 shares, a decline of 25.4% from the June 15th total of 264,900 shares. Based on an average daily volume of 119,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 1.3% of the company's stock are short sold. View Chemed's Current Options Chain.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Altria Group (MO), Target (TGT), Verizon Communications (VZ), AbbVie (ABBV), Boeing (BA), CVS Health (CVS), Chevron (CVX) and Johnson & Johnson (JNJ).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by many different retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.12%), Envestnet Asset Management Inc. (0.30%), Contravisory Investment Management Inc. (0.07%), Hexavest Inc. (0.01%) and 6 Meridian (0.00%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, and 6 Meridian. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, Spencer S Lee, and Walter L Krebs. View insider buying and selling activity for Chemed.

CHE stock was bought by a variety of institutional investors in the last quarter, including Contravisory Investment Management Inc., Envestnet Asset Management Inc., and Hexavest Inc.. View insider buying and selling activity for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $475.25.

Chemed has a market capitalization of $7.54 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe.

The official website for Chemed is www.chemed.com.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.